HCCscan

HCCscan

Reagents

Information

qPCR based kit for liver cancer (hepatocarcinoma, HCC) early screening. Through advanced methylation liquid biopsy technology, the risk of HCC at the current stage of the subject is assessed, enabling HCC to be detected at the curable stage. The new technology has a sensitivity much higher than that of traditional detection methods. Suitable for regular screening of people at risk of HCC (HBV/HCV infection, fatty liver, family history of HCC, long-term alcohol consumption, etc.). Changes in methylation levels are early events in the occurrence of HCC. Early detection and early treatment of HCC can greatly reduce treatment costs and improve the quality of life.
Genetron HealthH7.E36Genetron Health is a leading precision oncology platform company in China that specializes in the research and application of cancer molecular profiling. We provide early cancer screening, diagnosis and treatment recommendations, continuous disease monitoring and care, and biopharma development services that cover the entire spectrum of cancer management. The Company is committed to applying innovative genomics technology to cancer-related diagnosis and treatment and to ultimately defeating cancer. Our flagship products are as follows: HCCscan - Liver cancer early screening kit Lung Basic - Mutation detection kit for lung cancer companion diagnostics Onco sonar -Pan-solid tumors panel for target therapy and treatment response monitoring with liquid biopsy sample Onco Panscan - Pan-solid tumors panel for target therapy with tissue sample For more, kindly visit https://en.genetronhealth.com. We are looking for partners and looking forward to meeting you at Medlab Asia.

Log in